[go: up one dir, main page]

MA32616B1 - Composés destinés au traitement de neuropathies périphériques - Google Patents

Composés destinés au traitement de neuropathies périphériques

Info

Publication number
MA32616B1
MA32616B1 MA33677A MA33677A MA32616B1 MA 32616 B1 MA32616 B1 MA 32616B1 MA 33677 A MA33677 A MA 33677A MA 33677 A MA33677 A MA 33677A MA 32616 B1 MA32616 B1 MA 32616B1
Authority
MA
Morocco
Prior art keywords
group
alkyl group
alkyl
substituted
chosen
Prior art date
Application number
MA33677A
Other languages
Arabic (ar)
English (en)
Inventor
David Leppert
Erik Wallstroem
Barbara Nuesslein-Hildesheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40110984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32616(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32616B1 publication Critical patent/MA32616B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé de formule a1 ou a2 en vue d'une utilisation dans le traitement d'une neuropathie périphérique démyélinisante : dans lesquelles a représente coor5, opo(or5)2, po(or5)2, so2or5, por5or5 ou 1h-tétrazol-5-yle, r5 représentant h ou un groupe formant un ester, éventuellement alkyle en c1 à c6; w représente une liaison, un groupe alkylène en c1 à c3 ou alcénylène en c2 à c3; y représente un groupe aryle en c6 à c10 ou hétéroaryle en c2 à c9, par exemple hétéroaryle en c3 à c9, éventuellement substitué par 1 à 3 radicaux choisis parmi un atome d'halogène, oh, no2, un groupe alkyle en c1 à c6, alcoxy en c1 à c6; alkyle en c1 à c6 substitué par un atome d'halogène et alcoxy en c1 à c6 substitué par un atome d'halogène; z est choisi parmi les formules (i) : où les astérisques de z indiquent le point de fixation entre -c(r3)(r4)- et a de formule (ia) ou (ib), respectivement; r6 est choisi parmi un atome d'hydrogène et un groupe alkyle en c1 à c6; et j1 et j2 représentent indépendamment un groupe méthylène ou un hétéroatome choisi parmi s, o et nr5; où r5 est choisi parmi un atome d'hydrogène et un groupe alkyle en c1 à c6; et tout alkylène de z peut être en outre substitué par un à trois radicaux choisis parmi un groupe halogéno, hydroxy, alkyle en c1 à c6; ou r6 peut être fixé à un atome de carbone de y pour former un cycle de 5 à 7 chaînons; r1 représente un groupe aryle en c6 à c10 ou hétéroaryle en c2 à c9, par exemple hétéroaryle en c3 à c9, éventuellement substitué par un groupe alkyle en c1 à c6, aryle en c6 à c10, aryl en c6 à c10-alkyle en c1 à c4, hétéroaryle en c3 à c9, hétéroaryl en c3 à c9-alkyle en c1 à c4, cycloalkyle en c3 à c8, cycloalkyl en c3 à c8-alkyle en c1 à c4, hétérocycloalkyle en c3 à c8 ou hétérocycloalkyl en c3 à c8-alkyle en c1 à c4; où tout groupe aryle, hétéroaryle, cycloalkyle ou hétérocycloalkyle de r1 peut être substitué par 1 à 5 groupes choisis parmi un atome d'halogène, un groupe alkyle en c1 à c6, alcoxy en c1 à c6 et alkyle en c1 à c6 ou alcoxy en c1 à c6 substitué par un atome d'halogène; r2 représente h, un groupe alkyle en c1 à c6, alkyle en c1 à c6 substitué par un atome d'halogène, alcényle en c2 à c6 ou alkynyle en c2 à c6; et chacun de r3 et r4, indépendamment, représente h, un atome d'halogène, oh, un groupe alkyle en c1 à c6, alcoxy en c1 à c6 ou alkyle en c1 à c6 ou alcoxy en c1 à c6 substitué par un atome d'halogène; et leurs dérivés n-oxydes ou précurseurs, ou l'un de leurs sels pharmacologiquement acceptables, solvates ou hydrates.
MA33677A 2008-08-18 2011-03-07 Composés destinés au traitement de neuropathies périphériques MA32616B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08162517 2008-08-18
PCT/EP2009/060611 WO2010020610A1 (fr) 2008-08-18 2009-08-17 Composés destinés au traitement de neuropathies périphériques

Publications (1)

Publication Number Publication Date
MA32616B1 true MA32616B1 (fr) 2011-09-01

Family

ID=40110984

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33677A MA32616B1 (fr) 2008-08-18 2011-03-07 Composés destinés au traitement de neuropathies périphériques

Country Status (20)

Country Link
US (2) US20110144082A1 (fr)
EP (1) EP2326325B1 (fr)
JP (1) JP5624037B2 (fr)
KR (1) KR101618906B1 (fr)
CN (2) CN103271905A (fr)
AU (1) AU2009284128B2 (fr)
BR (1) BRPI0916968A2 (fr)
CA (1) CA2733508A1 (fr)
CL (1) CL2011000344A1 (fr)
ES (1) ES2526119T3 (fr)
IL (1) IL211189A (fr)
MA (1) MA32616B1 (fr)
MX (1) MX2011001832A (fr)
NZ (1) NZ606276A (fr)
PL (1) PL2326325T3 (fr)
PT (1) PT2326325E (fr)
RU (1) RU2523281C2 (fr)
SG (1) SG193803A1 (fr)
WO (1) WO2010020610A1 (fr)
ZA (1) ZA201101043B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
WO2017120124A1 (fr) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Modulateurs azétidine du récepteur de la sphingosine 1-phosphate
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
KR101958368B1 (ko) 2018-11-12 2019-03-14 윤종익 심층 시멘트 혼합 처리를 위한 저수심용 전용선
CN113262225B (zh) * 2021-03-25 2022-09-23 浙江大学医学院附属第一医院 Torin1在制备缓解药源性周围神经毒性的药物中的应用
CN119776509A (zh) * 2023-10-08 2025-04-08 华东师范大学 Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2300521C2 (ru) * 2000-12-01 2007-06-10 Астразенека Аб Новые производные миндальной кислоты и их применение в качестве ингибиторов тромбина
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
US7737835B2 (en) * 2006-06-29 2010-06-15 Siemens Vdo Automotive, S.A. De C.V. Hand held tire pressure monitoring system
SI2056807T1 (sl) * 2006-08-17 2012-12-31 University Of Chicago Zdravljenje vnetnih bolezni
AR068986A1 (es) * 2007-10-12 2009-12-23 Novartis Ag Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
US9149459B2 (en) * 2008-07-23 2015-10-06 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation

Also Published As

Publication number Publication date
SG193803A1 (en) 2013-10-30
US20110144082A1 (en) 2011-06-16
EP2326325A1 (fr) 2011-06-01
MX2011001832A (es) 2011-04-28
RU2523281C2 (ru) 2014-07-20
PT2326325E (pt) 2015-02-05
NZ606276A (en) 2013-10-25
US20140011797A1 (en) 2014-01-09
EP2326325B1 (fr) 2014-11-12
BRPI0916968A2 (pt) 2015-11-24
CL2011000344A1 (es) 2011-06-17
AU2009284128A1 (en) 2010-02-25
ES2526119T3 (es) 2015-01-07
IL211189A0 (en) 2011-04-28
KR20110043774A (ko) 2011-04-27
ZA201101043B (en) 2011-11-30
US8809316B2 (en) 2014-08-19
RU2011110115A (ru) 2012-09-27
CA2733508A1 (fr) 2010-02-25
KR101618906B1 (ko) 2016-05-09
HK1156229A1 (en) 2012-06-08
JP5624037B2 (ja) 2014-11-12
JP2012500247A (ja) 2012-01-05
CN103271905A (zh) 2013-09-04
AU2009284128B2 (en) 2013-07-18
WO2010020610A1 (fr) 2010-02-25
PL2326325T3 (pl) 2015-04-30
CN102186473B (zh) 2014-07-02
IL211189A (en) 2015-05-31
CN102186473A (zh) 2011-09-14

Similar Documents

Publication Publication Date Title
MA32616B1 (fr) Composés destinés au traitement de neuropathies périphériques
EP2532687A3 (fr) Catalyseurs à base de metallocènes pontés
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
ATE533489T1 (de) Behandlung von multiplem myelom
SMP201100019B (it) Composti organici
BR112014000465A2 (pt) catalisadores
BRPI1009637A2 (pt) composto, composição e uso de um composto
MX2020009511A (es) Tratamiento o prevención de eventos cardiovasculares.
UA109638C2 (uk) Сполуки та спосіб зниження рівня сечової кислоти
NZ594537A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2008100867A3 (fr) Nouveaux inhibiteurs de réplication du virus de l'hépatite c
BR112013028486A2 (pt) método para promover crescimento de planta
JO2732B1 (en) Organic compounds
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
MX363956B (es) Agente de control de plagas.
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
BRPI0708685B8 (pt) composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
WO2008107502A8 (fr) Composition destinée à traiter des maladies infectieuses
BR112014027859A2 (pt) composição detergente para lavagem de roupas compreedendo uma partícula que tem um agente de tonalização e argila
BR112013028598A2 (pt) método para promover o crescimento de plantas
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
BR112014014347A2 (pt) misturas de ácidos difosfínicos e ácidos alquilfosfônicos, processo para produção das mesmas e uso das mesmas
NZ593048A (en) Composition for controlling plant diseases comprising an alkoxyphenylacetic acid compound and at least one compound selected from tolclofos-methyl, metalaxyl and mefenoxam
EA201070781A1 (ru) Производные оксадиазола, активные на сфингозин-1-фосфате (s1p)
NO20092076L (no) Ny fremgangsmate for fremstilling av 4,4'-(1-metyl-1,2-etandiyl)-bis-(2,6-piperazindion)